Archives for May 23, 2006

← 2006

Laureate Pharma wins Seattles Genetics contract

By  Gregory Roumeliotis

Contract biomanufacturing firm Laureate has won a contract to produce Seattle Genetics' humanised monoclonal antibody product candidates for clinical trial, adding to its experience in monoclonal antibody development.

Child friendly packaging made cost friendly too

By  Kirsty Barnes

Amcor Flexibles has launched a new tear open feature for foil drug packaging that it claims is both child resistant and senior friendly and cheaper to make than current methods.

Abraxis BioScience adds facility to investigate SPARC

By  Wai Lang Chu

Abraxis Bioscience has added a research facility to expand the company's research and process development capabilities that use the company's nab technology platform, which identifies new chemical entities and exploitation of the SPARC pathway and its...

GE Healthcare and MDS Pharma launch cell genotoxicity predictor

By Wai Lang Chu

General Electric and MDS Pharma Services announced today the availability of a new, automated in vitro micronucleus assay that will form part of a broad panel of drug discovery safety assessments offered by MDS Pharma Services pharmacology division.

Wasag hints at price hikes despite profits quadrupling

By  Gregory Roumeliotis

Specialty chemicals group H&R Wasag witnessed tremendous growth in the first quarter of 2006, as stable crude oil prices allowed it to increase prices and volumes in the pharmaceutical raw materials it sells.

EMEA approves vaccine containing Delta's recombinant human albumin

By  Gregory Roumeliotis

The European Medicines Agency (EMEA) has given Sanofi Pasteur the green light to market a childhood vaccine containing Delta's Recombumin, a recombinant human albumin which offers the world's first and only animal-free alternative to human serum...

New controlled-release polymer shows promise

By  Kirsty Barnes

A new polymer drug delivery technology developed by Dutch firm OctoPlus has cleared Phase I trials for the first time, showing promise in a new controlled release treatment of chronic hepatitis C.

CAT profits attributed to arthritis royalties

By  Wai Lang Chui

Cambridge Antibody Technology (CAT) posted a first-half profit for the year that was attributed to royalty payments for its Humira rheumatoid arthritis drug.

Phosphagenics facility could lead to more deals

By  Jess Halliday

Phosphagenics is constructing a new tocopheryl phosphates manufacturing plant in Melbourne, Australia - a project that paves the way for future licensing agreements and could encourage the use of its technology in more nutraceutical and pharmaceutical...

Novasep zeroes in on the chromatography market

By  Gregory Roumeliotis

French separations specialist Novasep has launched two new chromatography systems, promising new levels of efficency in preparative high performance liquid chromatography (HPLC).